Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Q BioMed Begins Preparations to Test Drug Targeting a Patient Subset on the Autism Spectrum

By Catherine Sbeglia | October 10, 2018

Q BioMed Inc., a biotechnology acceleration company, is in the beginning stages of developing QBM001, its Autistic Spectrum Disorder (ASD) drug program for nonverbal or minimally verbal autistic children.

The patent pending QBM-001 drug technology is being tested for pediatric developmental nonverbal disorder in toddlers within the autism spectrum disorders. Q BioMed says the company is focusing on QBM001 candidate formulations that seek to provide an improved safety profile in preclinical studies. In preparation for the clinical trials, Q BioMed has visited a number of potential trial sites in the U.S. and Europe over the last nine months.

QBM-001 targets toddlers with pediatric developmental nonverbal disorder. An underlying commonality of this subgroup is elevated blood markers that lead to developmental delay, an autism diagnosis, and eventual nonverbal or very minimally verbal capability for the rest of their lives.

Because there is currently no diagnostic tool to identify risk of nonverbal or very minimally verbal subgroup of ASD at an early age, Q BioMed has been evaluating diagnostic options that could offer a way to diagnose children as early as two years of age. These tools are expected to be part of the upcoming clinical trial to help validate them as potential biomarkers.

Q BioMed indicated that it will announce these partnerships in the coming months as the regulatory filings required for orphan drug designation and an IND to initiate the planned clinical trial are submitted.

Q BioMed is preparing partnerships with a Contract and Development Manufacturing Organization (CDMO) to start manufacturing, and Contract Research Organizations (CROs) to finish preclinical studies.

According to Q BioMed, there are approximately 18,000 new cases of pediatric developmental nonverbal disorder in the US each year and a similar amount in Europe. The majority of the children are diagnosed as young children and fall within the autism and epilepsy spectrum disorders. Individually, the economic costs for toddlers that become non or minimally verbal is ten million dollars on average per person over their life. 

(Source: Q BioMed Inc.)


Filed Under: Drug Discovery and Development

 

Related Articles Read More >

Collage of close-up male and female eyes isolated on colored neon backgorund. Multicolored stripes. Concept of equality, unification of all nations, ages and interests. Diversity and human rights
How a ‘rising tide’ of inclusivity is transforming clinical trials
Mary Marcus appointed CEO of NewAge Industries
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Data analytics tools help doctors analyze trends in patient outcomes and population health.
External comparator studies: What researchers need to know to minimize bias
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Voices
    • Views
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE